US › Healthcare

Cognition Therapeutics Inc (CGTX)

US · Healthcare · Biotechnology

$0.69+8.12%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

Net profit

$-4.1M

EPS

$-0.04

EPS estimate

$-0.07

EPS came in at -0.04 against a street estimate of -0.07 — a beat of 42.9%.

Key statistics

Market cap

$60.4M

Forward P/E

0.0

P/B

2.01

Book value

$0.35

EPS (TTM)

$-0.16

52-week high

$1.82

52-week low

$0.55

50-day MA

$0.90

200-day MA

$1.06

Beta

1.80

Analyst view

Analysts rate Cognition Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $3.33.

Shareholding

Insiders

1.29%

Institutions

23.82%

Largest institutional holders

Fund	Stake
BIOS CAPITAL MANAGEMENT, LP	6.31%
Davenport & Company LLC	4.48%
Vanguard Capital Management, LLC	3.62%
BlackRock Inc	1.33%
Chescapmanager LLC	1.05%
Geode Capital Management, LLC	0.96%
Renaissance Technologies Corp	0.73%
Hilton Capital Management, LLC	0.58%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cognition Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.